Joshua Brostoff
About Joshua Brostoff
Joshua Brostoff serves as the Medical Director at Aimmune Therapeutics since 2019 and has extensive experience in the pharmaceutical industry, including previous roles at Sanofi and NHS. He is also a Visiting Lecturer in Medical Ethics at King's College London and holds multiple medical qualifications.
Work at Aimmune Therapeutics
Joshua Brostoff has served as Medical Director at Aimmune Therapeutics since 2019. In this role, he contributes to the strategic direction and medical oversight of the company's projects. His expertise in clinical development and public health supports Aimmune's mission in advancing therapies, particularly in the field of immunology.
Previous Experience at Sanofi
Before joining Aimmune Therapeutics, Joshua Brostoff worked at Sanofi in various roles. He was a Senior Medical Advisor from 2016 to 2018 and a Medical Advisor from 2014 to 2016, both based in Guildford, United Kingdom. Additionally, he served as Clinical Study Director at Sanofi from 2018 to 2019, overseeing clinical trials and ensuring compliance with regulatory standards.
Education and Expertise
Joshua Brostoff holds a Bachelor of Science (BSc) in Population Health from University College London and an MBChB in Medicine from The University of Birmingham. He furthered his education with a Master of Arts (M.A.) in Medical Ethics and Law from King's College London. His qualifications include MRCP, MRCEM, DRCOG, DipMedEd, DTM&H, DipPharmMed, DLM, and FHEA, demonstrating a comprehensive background in medical practice and education.
Background in NHS
Joshua Brostoff has a decade of experience working within the NHS, where he served as a Physician specializing in general medicine and infectious diseases from 2003 to 2013 in London. This role provided him with extensive clinical experience and a solid foundation in patient care and medical practice.
Interests and Career Plans
Joshua Brostoff has expressed a keen interest in clinical development, global and public health, vaccines, and aging/neurodegenerative diseases. He aims to transition into more strategic roles within smaller companies, including start-ups and biotechs, to leverage his extensive experience in the pharmaceutical sector.